Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa...
04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible ...
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (IS...
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6) 24.03.2023 / 17:00 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT I...
EQS-News: MorphoSys AG / Key word(s): Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Prov...